Rare Infectious Disease News

Spotlight On

Ebola virus disease

Ebola virus disease (EVD) is a deadly disease with occasional outbreaks that occur mostly on the African continent

Prevelance

<1 / 1 000 000

< 331

US Estimated

< 514

Europe Estimated

Age of Onset

ageofonset-all.svg

ICD-10

A98.4

Inheritance

Autosomal dominant

no.svg

Autosomal recessive

no.svg

Mitochondrial/Multigenic

no.svg

X-linked dominant

no.svg

X-linked recessive

no.svg

Rare View

5 Facts you should know

FACT

1

 A viral hemorrhagic fever in humans and other primates, caused by ebolaviruses

FACT

2

Symptoms typically start anywhere between two days and three weeks after becoming infected with the virus

FACT

3

The first symptoms are usually fever, sore throat, muscle pain, and headaches

FACT

4

These are usually followed by vomiting, diarrhoea, rash anddecreased liver and kidney function, at which point, some people begin to bleed both internally and externally

FACT

5

 The disease kills between 25% and 90% of those infected—about 50% on average

Ebola virus disease is also know as...

Ebola virus disease

Ebola; Ebola hemorrhagic fever (EHF)

What’s your Rare IQ?

The worst known Ebola epidemic lasted from late 2013 until early 2016. Which African country recorded the most cases of the Ebola virus?

Top Clinical Trials

TitleDescriptionPhasesStatusInterventionsMore Information
Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Years and in Their Adults and/or Children Relatives Living in Lambaréné, GabonLA rVSVΔG-ZEBOV-GP -02-PED is a Phase 1/2, randomized, controlled open label trial. The LA rVSVΔG-ZEBOV-GP -02-PED trial aims primarily to assess the clinical significance of shedding of the rVSV RNA following vaccination with the rVSVΔG-ZEBOV-GP vaccine in children.Phase 1|Phase 2RecruitingBiological: rVSVΔG-ZEBOV-GP, V920Click here for more information
An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus DiseaseOpen-label safety, tolerability, pharmacokinetics and immunogenicity study in three dose escalation groupsPhase 1RecruitingDrug: GamezumabClick here for more information
A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant WomenThe purpose of this study is: a) to assess adverse maternal/fetal outcomes in pregnant women randomized to receive the 2- dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo [Group A]) and in control women (unvaccinated pregnant women [Group B]);Phase 3RecruitingBiological: Ad26.ZEBOV|Biological: MVA-BN-FiloClick here for more information

Top Treatments in Research

AgentClass/Mechanism of ActionDevelopment StatusCompanyClinical StudiesMore Information
rVSVΔG-ZEBOV-GP, V920 (Erbevo)ERVEBO is a replication-competent, live, attenuated recombinant vesicular stomatitis virus (rVSV) vaccinePhase 1/2Centre de Recherche Médicale de Lambaréné
Collaborator:
Merck Sharp & Dohme Corp.
Click here for more informationn/a
GamezumabMonoclonal antibodies against Ebola virus diseasePhase 1Gamaleya Research Institute of Epidemiology and MicrobiologyClick here for more informationClick here for more information
Ad26.ZEBOV|Biological: MVA-BN-FiloAdenovirus serotype 26 encoding the ebola virus mayinga glycoprotein (Ad26.ZEBOV)Phase 3Janssen Vaccines & Prevention B.V.Click here for more informationn/a